Evidence map›Paper›PMID 39434959›Full record

ArticleResearch and practice in thrombosis and haemostasis2024

Impact of the VTE-PREDICT calculator on clinicians' decision making in fictional patients with venous thromboembolism: a randomized controlled trial.

Daniël Duijzer, Maria A de Winter, Marc Carrier, Alexander T Cohen, John-Bjarne Hansen, Karin A H Kaasjager, Ajay K Kakkar, Saskia Middeldorp, Henrik T Sørensen, Frank L J Visseren and 3 more

Abstract read
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Managing patients with a history of arterial disease and new venous thromboembolism.Hematology. American Society of Hematology. Education Program · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Daniël DuijzerDepartment of Acute Internal Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
Maria A de WinterDepartment of Acute Internal Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
Marc CarrierDepartment of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Alexander T CohenDepartment of Haematological Medicine, Guys and St Thomas' Hospitals, King's College London, London, United Kingdom.
John-Bjarne HansenDepartment of Clinical Medicine, Thrombosis Research Center (TREC), Universitetet i Tromsø - The Arctic University of Norway, Tromsø, Norway.
Karin A H KaasjagerDepartment of Acute Internal Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
Ajay K KakkarThrombosis Research Institute London, London, United Kingdom.
Saskia MiddeldorpDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
Henrik T SørensenDepartment of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.
Frank L J VisserenDepartment of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
Philip S WellsDepartment of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Jannick A N DorresteijnDepartment of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
Mathilde NijkeuterDepartment of Acute Internal Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: After 3 months of anticoagulation for venous thromboembolism (VTE), the decision needs to be made whether to stop anticoagulation or extend treatment indefinitely. The VTE-PREDICT calculator can be used to estimate individual risks of VTE recurrence and bleeding to guide this decision. Objectives: To evaluate the impact of predicted individual risks of recurrence and bleeding on clinicians' decisions on anticoagulation duration and to assess usefulness of the VTE-PREDICT calculator. Methods: A randomized controlled trial and within-subject study was conducted among clinicians treating VTE patients. The clinicians were asked to complete an online survey containing 6 fictional case vignettes. Group A proposed anticoagulant duration for each case without additional information first and subsequently after seeing calculator-predicted risks (within-subject analysis). Group B was directly provided with calculator risks and proposed treatment duration for each case vignette (for comparison with group A results in a randomized controlled trial analysis). Then, group B received questions on usefulness and credibility of the calculator. Results: Forty-five clinicians were assigned to group A and 48 to B. Overall, group A did not propose different anticoagulation durations than group B. However, individual clinicians in group A changed proposed duration in 35% of the cases after seeing the calculator risks. The calculator was considered useful and credible by most clinicians. Conclusion: Overall, use of the VTE-PREDICT calculator did not affect proposed anticoagulation duration. However, individual clinicians frequently changed their proposed duration after using the calculator, especially for patients with high bleeding risk.

Indexed as

clinical decision-makinghemorrhagepersonalized medicinerandomized controlled trialvenous thromboembolism

Identifiers

PMID39434959
PMCPMC11491954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.